2024
Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
Kiwan A, Kewan T, Bravo-Perez C, Visconte V, Gurnari C, Durmaz A, Siddon A, Halene S, Sethi T, Maciejewski J, Foss F. Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment. Blood 2024, 144: 4436. DOI: 10.1182/blood-2024-209344.Peer-Reviewed Original ResearchT-cell rearrangementArea under the curveGranular lymphocytic leukemiaMonoclonal gammopathyUnivariate analysisRheumatoid arthritisMyelodysplastic syndromeClonal hematopoiesisMedian ageLymphocytic leukemiaFactors associated with anemiaAbsence of CD4Associated with cytopeniaHistory of rheumatoid arthritisAssociated with neutropeniaExpression of CD5Presence of splenomegalyTreatment requirementsAssociated with anemiaMultivariate logistic regression modelPrimary etiological factorMultivariate regressionPersonalized treatment strategiesUnivariate logistic regressionAssociated with treatment
2017
Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorDrug therapyCLL therapyChronic lymphocytic leukemia patientsElderly unfit patientsAdditional treatment optionsDuration of treatmentRepertoire of drugsImmune effector responsesLymphocytic leukemia patientsChronic lymphocytic leukemiaLong-term toxicityUnfit patientsPatient ageCD20 antibodyRisk stratificationCLL treatmentAsymptomatic individualsTherapy optionsTreatment optionsEffector responsesLeukemia patientsLymphocytic leukemiaCLL cellsTreatment approaches
2015
Ibrutinib in chronic lymphocytic leukemia
Reddy N, Sethi T. Ibrutinib in chronic lymphocytic leukemia. International Journal Of Hematologic Oncology 2015, 4: 143-150. DOI: 10.2217/ijh.15.15.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorTyrosine kinaseKey survival pathwaysMalignant B cellsSignal transductionKinase pathwayBruton's tyrosine kinaseSurvival pathwaysCell survivalSignal triggersB cellsPathwayChronic lymphocytic leukemiaB cell proliferationKey roleTumor microenvironmentTumor malignancyCellsTransductionKinaseLymphocytic leukemia